Usefulness of limited sampling strategy for mycophenolic acid area under the curve considering postoperative days in living-donor renal transplant recipients with concomitant prolonged-release tacrolimus

[1]  G. Evatt,et al.  EST-SSRs as a resource for population genetic analyses , 2007, Heredity.

[2]  D. Hesselink,et al.  Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[3]  H. Houchi,et al.  Limited sampling strategy for the estimation of mycophenolic acid area under the concentration-time curve treated in Japanese living-related renal transplant recipients with concomitant extended-release tacrolimus. , 2013, Biological & pharmaceutical bulletin.

[4]  P. Marquet,et al.  Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. , 2011, Transplantation reviews.

[5]  B. Tönshoff,et al.  Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[6]  M. Hayakari,et al.  Early Phase Limited Sampling Strategy Characterizing Tacrolimus and Mycophenolic Acid Pharmacokinetics Adapted to the Maintenance Phase of Renal Transplant Patients , 2009, Therapeutic drug monitoring.

[7]  M. Hayakari,et al.  Limited Sampling Strategy for Simultaneous Estimation of the Area Under the Concentration-Time Curve of Tacrolimus and Mycophenolic Acid in Adult Renal Transplant Recipients , 2008, Therapeutic drug monitoring.

[8]  B. Kaplan,et al.  Therapeutic monitoring of mycophenolate mofetil. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[9]  W. Weimar,et al.  Predicting the Usefulness of Therapeutic Drug Monitoring of Mycophenolic Acid: A Computer Simulation , 2005, Therapeutic drug monitoring.

[10]  Leslie M Shaw,et al.  Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. , 2002, Clinical chemistry.

[11]  G. Klintmalm,et al.  A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  L. Shaw,et al.  Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. , 2001, Clinical biochemistry.

[13]  L. Shaw,et al.  Mycophenolic acid concentrations are associated with cardiac allograft rejection. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  L. Shaw,et al.  Mycophenolic Acid Area under the Curve Values in African American and Caucasian Renal Transplant Patients Are Comparable , 2000, Journal of clinical pharmacology.

[15]  Jean‐Paul Squifflet,et al.  The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation , 1998, Clinical pharmacology and therapeutics.

[16]  D. Renlund,et al.  A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. , 1998, Transplantation.

[17]  A. Nicholls.  Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. , 1998, Clinical biochemistry.

[18]  L. Shaw,et al.  Therapeutic monitoring of mycophenolic acid: A consensus panel report , 1998 .

[19]  A. Nicholls,et al.  Clinical Pharmacokinetics of Mycophenolate Mofetil , 1998, Clinical pharmacokinetics.

[20]  J. Squifflet,et al.  A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. , 1998, Transplantation.

[21]  M. Hale,et al.  Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. , 1996, Transplantation proceedings.

[22]  European Cooperative Study Group.  Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection , 1995, The Lancet.

[23]  P Fauchald,et al.  PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .

[24]  S. Suzuki,et al.  Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan. , 1995, Transplantation proceedings.

[25]  J. Squifflet,et al.  Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. , 2001, Clinical chemistry.